



20 December 2021

Kalapa Germany, acquires a minority stake in, and collaborates with, German Patient Support Program specialist

Highlights

- **Kalapa Germany acquires 5% minority stake in German Patient Support Programme specialist (1Care Innohealth GmbH) and will collaborate in future activities including the generation of real-world evidence data**
- **A Patient Support Programme is pharmaceutical industry best practice enabling support for patients outside of their contact with their doctor**
- **Kalapa Germany has developed the first German PSP for cannabis medicine in collaboration with 1Care and will support patients who receive products from group company, CanPharma**

Health House International Limited (**ASX:HHI**) (**Health House** or **the Company**, together with the entities it controls **the Group**) is pleased to announce its wholly-owned subsidiary Kalapa Germany (**Kalapa**) has entered into an agreement with German Patient Support Programmes specialist, 1Care Innohealth GmbH (**1Care**), to acquire a 5% minority stake and to collaborate in future related activities.

A Patient Support Programme (**PSP**) is a pharmaceutical industry best practice which provides support for patients in the use of medicine outside of their contact with their prescriber. A PSP gives additional support to prescribers who often don't have time to address patients' day-to-day needs. On the other hand, patients can contact the PSP with enquiries between their regular doctors' appointments. A PSP allows the generation of data around the effects of the therapy and the improvement of quality of life.

Kalapa has established the first PSP in the cannabis sector for patients prescribed - Group company - CanPharma's products: CanPharma Care (www.canpharma-care.de).

The CanPharma Care PSP aims at providing cannabis patients who are prescribed CanPharma products a 360-degree support via a telephone hotline after prescription; the service includes support with:

- usage of the prescribed medicinal cannabis; and
- a coaching service and easy access to an expert.

The close support offered by the programme increases the chances of adherence of cannabis patients to their treatment, as they feel well accompanied through this new treatment and otherwise may stop using the product.

1Care has supported Kalapa in the establishment of the CanPharma Care PSP. 1Care was founded by experts with many years' experience in setting up PSPs for pharmaceutical companies Teva Pharmaceuticals, Shire Deutschland and others indications including Multiple Sclerosis and Fabry disease.

As part of the agreement, Kalapa Germany acquires a minority stake in 1Care in order to collaborate with 1 Care in the future, especially when it comes to the generation of real - world evidence data and its usage for optimization of therapies..

Kalapa Germany Managing Director, Gesa Riedewald, said: *"We are happy to enter in this long-term collaboration with 1Care. We are in the process of developing an app which is to accompany the patients over the entire patient's journey which we will deploy through the PSP. We aim to digitalize the patient's journey and to process this data in order to optimize treatments for patients. The improvement of patients' condition and well-being continues to be our top priority."*

Founder and CEO of 1Care, Frank Bialkowski, comments: *"Treatment with medicinal cannabis patients differs from conventional pharmaceutical treatments, since it is far from standardized and the delivery system is often not familiar to them. Therefore, a PSP is ideal for cannabis patients as they may need ongoing support as they get accustomed to their treatment."*

Health House Chief Executive Officer, David Attwood said: *"The collaboration between 1Care and Kalapa manifests the importance of the patient-centric approach for cannabis treatments. It all comes back to the data which are generated and can be used for product development and optimization of treatments. The experience gained sets Kalapa up to contribute to clinical trials."*

This announcement has been approved and authorised for release by the board of Health House International Limited.

David Attwood
Chief Executive Officer

About Health House (www.healthhouse.com.au)

Health House International and the entities it controls (**the Group**) is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Group is a fully licenced and regulated specialised importer, exporter and distributor currently distributing medicinal cannabis products from 14 producers to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. In the UK and Germany, the Group holds all relevant licences (including GMP manufacturing), Wholesale Dealers and Controlled Drugs licences the Company supplies pharmacies, hospitals, government departments and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe. The Group also integrates education of patients and healthcare professionals in the use of medicinal cannabis as a core part of its activities and is developing digital tools to enable a holistic understanding of usage.

Address

Level 3, 101 St Georges Tce
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: admin@healthhouse.com.au
W: www.healthhouse.com.au
ACN 149 197 651

Contact:

David Attwood
David.attwood@healthhouse.com.au

Tim Slate
Tim.slate@healthhouse.com.au